New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 14, 2013
12:14 EDTZIOPZiopharm confirms PFS is endpoint in palifosfamide trial, Feuerstein says
Ziopharm confirmed that progression-free survival, or PFS, is now an acceptable endpoint for approval in palifosfamide's Phase III trial, The Street's Adam Feuerstein said via Twitter, citing a company spokesperson. Shares of Ziopharm are up 5% to $5.53 in early afternoon trading.
News For ZIOP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for ZIOP

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use